Trials / Unknown
UnknownNCT02583438
Evaluate the Effect of Saxagliptin on Gut Microbiota in Patients With Newly Diagnosed Type 2 Diabetes
Beijing Chao-yang Hospital, Capital Medical University
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- Sponsor
- Beijing Chao Yang Hospital · Academic / Other
- Sex
- All
- Age
- 20 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The intestinal microflora imbalance has been associated with obesity and type 2 diabetes. The researchers' study aimed to investigate the effect of saxagliptin on gut microbiota in patients with newly diagnosed type 2 diabetes.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Saxagliptin (Bristol-Myers Squibb Company) | 6-month treatment of Saxagliptin 5mg Qd |
Timeline
- Start date
- 2015-10-01
- Primary completion
- 2017-10-01
- Completion
- 2018-01-01
- First posted
- 2015-10-22
- Last updated
- 2015-10-22
Source: ClinicalTrials.gov record NCT02583438. Inclusion in this directory is not an endorsement.